Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Feb;69(2):299–306. doi: 10.1038/bjc.1994.55

Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro.

A P Jekunen 1, R D Christen 1, D R Shalinsky 1, S B Howell 1
PMCID: PMC1968703  PMID: 7905279

Abstract

Taxol, a unique tubulin active agent, was found to demonstrate a marked schedule-dependent synergistic interaction with cisplatin (DDP) in the killing of human ovarian carcinoma 2008 cells in vitro as determined by median effect analysis. The interaction was highly synergistic when 19 h taxol exposure was followed by 1 h concurrent exposure to taxol and DDP. The combination indices (CIs) on this schedule were 0.11 +/- 0.1, 0.25 +/- 0.15 and 0.39 +/- 0.14 at 20%, 50% and 80% cell kill respectively. However, the interaction was antagonistic when 1 h exposure to DDP was followed by 20 h exposure to taxol, or when cells were exposed to DDP and taxol for 1 h concurrently. When taxol preceded DDP, synergy was also observed with the 11-fold DDP-resistant 2008/C13*5.25 subline, which yielded CI values of 0.21 +/- 0.02, 0.30 +/- 0.11 and 0.31 +/- 0.17 at 20%, 50% and 80% cell kill respectively. At an IC50 concentration, taxol had no effect on [3H]cis-dichloro(ethylenediamine) platinum uptake, on the permeability of the plasma membrane or on glutathione or metallothionein levels in 2008 or 2008/C13*5.25 cells. Mitotic arrest in these cells was observed only at taxol concentrations well above those required for synergy with DDP, suggesting that the mechanism underlying the synergistic interaction was not a taxol-induced alteration in cell cycle kinetics. Of additional interest was the fact that the 2008/C13*5.25 cells were hypersensitive to taxol, and that this was partially explained by an alteration in the biochemical pharmacology of taxol. Although cellular taxol accumulation reached steady state within 2 h in both cell lines, taxol efflux was slower and the taxol was more extensively bound in 2008/C13*5.25 cells than in 2008 cells. In addition, the 2008/C13*5.25 cells had only 55% of the parental levels of beta-tubulin content. However, in another pair of DDP-sensitive and -resistant ovarian cell lines no taxol hypersensitivity and no change in beta-tubulin content was observed, indicating that the DDP-resistant and taxol-hypersensitive phenotypes do not segregate together. We conclude that taxol interacts synergistically with DDP in a manner that is highly schedule dependent, and that the hypersensitivity of 2008/C13*5.25 cells no taxol is unrelated to the mechanism of synergy. These in vitro observations suggest that drug schedule will be an important determinant of the activity and toxicity of the DDP and taxol drug combination in clinical studies.

Full text

PDF
299

Images in this article

303Figure 6
on p.303

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews P. A., Murphy M. P., Howell S. B. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res. 1985 Dec;45(12 Pt 1):6250–6253. [PubMed] [Google Scholar]
  2. Andrews P. A., Velury S., Mann S. C., Howell S. B. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res. 1988 Jan 1;48(1):68–73. [PubMed] [Google Scholar]
  3. Berenbaum M. C. What is synergy? Pharmacol Rev. 1989 Jun;41(2):93–141. [PubMed] [Google Scholar]
  4. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  5. Chibber R., Ord M. J. The mutagenic and carcinogenic properties of three second generation antitumour platinum compounds: a comparison with cisplatin. Eur J Cancer Clin Oncol. 1989 Jan;25(1):27–33. doi: 10.1016/0277-5379(89)90047-3. [DOI] [PubMed] [Google Scholar]
  6. Chou T. C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. doi: 10.1016/0065-2571(84)90007-4. [DOI] [PubMed] [Google Scholar]
  7. Christen R. D., Jekunen A. P., Jones J. A., Thiebaut F., Shalinsky D. R., Howell S. B. In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J Clin Invest. 1993 Jul;92(1):431–440. doi: 10.1172/JCI116585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Darzynkiewicz Z., Traganos F., Sharpless T., Melamed M. R. Interphase and metaphase chromatin. Different stainability of DNA with acridine orange after treatment at low pH. Exp Cell Res. 1977 Nov;110(1):201–214. doi: 10.1016/0014-4827(77)90286-5. [DOI] [PubMed] [Google Scholar]
  9. Darzynkiewicz Z., Traganos F., Sharpless T., Melamed M. R. Recognition of cells in mitosis by flow cytofluormetry. J Histochem Cytochem. 1977 Jul;25(7):875–880. doi: 10.1177/25.7.70457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dean P. N., Jett J. H. Mathematical analysis of DNA distributions derived from flow microfluorometry. J Cell Biol. 1974 Feb;60(2):523–527. doi: 10.1083/jcb.60.2.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. DiSaia P. J., Sinkovics J. G., Rutledge F. N., Smith J. P. Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors. Am J Obstet Gynecol. 1972 Dec 1;114(7):979–989. doi: 10.1016/0002-9378(72)90109-3. [DOI] [PubMed] [Google Scholar]
  12. Dornish J. M., Melvik J. E., Pettersen E. O. Reduced cellular uptake of cis-dichlorodiammine-platinum by benzaldehyde. Anticancer Res. 1986 Jul-Aug;6(4):583–588. [PubMed] [Google Scholar]
  13. Dornish J. M., Pettersen E. O. Protection from cis-dichlorodiammineplatinum-induced cell inactivation by aldehydes involves cell membrane amino groups. Cancer Lett. 1985 Dec;29(3):235–243. doi: 10.1016/0304-3835(85)90133-8. [DOI] [PubMed] [Google Scholar]
  14. Frost P., Abbruzzese J. L., Hunt B., Lee D., Ellis M. Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells. Cancer Res. 1990 Aug 1;50(15):4572–4577. [PubMed] [Google Scholar]
  15. Gunning P., Ponte P., Okayama H., Engel J., Blau H., Kedes L. Isolation and characterization of full-length cDNA clones for human alpha-, beta-, and gamma-actin mRNAs: skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed. Mol Cell Biol. 1983 May;3(5):787–795. doi: 10.1128/mcb.3.5.787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hayward I. P., Hurst T., Parsons P. G., Khoo S. K. Combination chemotherapy tested in a short-term thymidine incorporation assay in primary cultures of ovarian adenocarcinomas. Int J Cell Cloning. 1992 May;10(3):182–189. doi: 10.1002/stem.5530100309. [DOI] [PubMed] [Google Scholar]
  17. Hofmann J., Ueberall F., Posch L., Maly K., Herrmann D. B., Grunicke H. Synergistic enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by the ether lipid analogue BM41440, an inhibitor of protein kinase C. Lipids. 1989 Apr;24(4):312–317. doi: 10.1007/BF02535169. [DOI] [PubMed] [Google Scholar]
  18. Jekunen A., Vick J., Sanga R., Chan T. C., Howell S. B. Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro. Cancer Res. 1992 Jul 1;52(13):3566–3571. [PubMed] [Google Scholar]
  19. Karin M., Richards R. I. Human metallothionein genes--primary structure of the metallothionein-II gene and a related processed gene. Nature. 1982 Oct 28;299(5886):797–802. doi: 10.1038/299797a0. [DOI] [PubMed] [Google Scholar]
  20. Keane T. E., Rosner G., Donaldson J. T., Norwood D. L., Poulton S. H., Walther P. J. Dipyridamole-cisplatin potentiation: enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers. J Urol. 1990 Oct;144(4):1004–1009. doi: 10.1016/s0022-5347(17)39647-7. [DOI] [PubMed] [Google Scholar]
  21. Larsen J. K., Munch-Petersen B., Christiansen J., Jørgensen K. Flow cytometric discrimination of mitotic cells: resolution of M, as well as G1, S, and G2 phase nuclei with mithramycin, propidium iodide, and ethidium bromide after fixation with formaldehyde. Cytometry. 1986 Jan;7(1):54–63. doi: 10.1002/cyto.990070108. [DOI] [PubMed] [Google Scholar]
  22. Lidor Y. J., Shpall E. J., Peters W. P., Bast R. C., Jr Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. Int J Cancer. 1991 Nov 11;49(5):704–710. doi: 10.1002/ijc.2910490513. [DOI] [PubMed] [Google Scholar]
  23. Mann S. C., Andrews P. A., Howell S. B. Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer. 1991 Jul 30;48(6):866–872. doi: 10.1002/ijc.2910480613. [DOI] [PubMed] [Google Scholar]
  24. McGuire W. P., Rowinsky E. K., Rosenshein N. B., Grumbine F. C., Ettinger D. S., Armstrong D. K., Donehower R. C. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989 Aug 15;111(4):273–279. doi: 10.7326/0003-4819-111-4-273. [DOI] [PubMed] [Google Scholar]
  25. Peyrot V., Briand C., Momburg R., Sari J. C. In vitro mechanism study of microtubule assembly inhibition by cis-dichlorodiammine-platinum(II). Biochem Pharmacol. 1986 Feb 1;35(3):371–375. doi: 10.1016/0006-2952(86)90207-8. [DOI] [PubMed] [Google Scholar]
  26. Rowinsky E. K., Cazenave L. A., Donehower R. C. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990 Aug 1;82(15):1247–1259. doi: 10.1093/jnci/82.15.1247. [DOI] [PubMed] [Google Scholar]
  27. Rowinsky E. K., Donehower R. C. Taxol: twenty years later, the story unfolds. J Natl Cancer Inst. 1991 Dec 18;83(24):1778–1781. doi: 10.1093/jnci/83.24.1778. [DOI] [PubMed] [Google Scholar]
  28. Rowinsky E. K., Gilbert M. R., McGuire W. P., Noe D. A., Grochow L. B., Forastiere A. A., Ettinger D. S., Lubejko B. G., Clark B., Sartorius S. E. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol. 1991 Sep;9(9):1692–1703. doi: 10.1200/JCO.1991.9.9.1692. [DOI] [PubMed] [Google Scholar]
  29. Röyttä M., Laine K. M., Härkönen P. Morphological studies on the effect of taxol on cultured human prostatic cancer cells. Prostate. 1987;11(1):95–106. doi: 10.1002/pros.2990110112. [DOI] [PubMed] [Google Scholar]
  30. Schiff P. B., Fant J., Horwitz S. B. Promotion of microtubule assembly in vitro by taxol. Nature. 1979 Feb 22;277(5698):665–667. doi: 10.1038/277665a0. [DOI] [PubMed] [Google Scholar]
  31. Weinstein B., Solomon F. Phenotypic consequences of tubulin overproduction in Saccharomyces cerevisiae: differences between alpha-tubulin and beta-tubulin. Mol Cell Biol. 1990 Oct;10(10):5295–5304. doi: 10.1128/mcb.10.10.5295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Wiernik P. H., Schwartz E. L., Einzig A., Strauman J. J., Lipton R. B., Dutcher J. P. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol. 1987 Aug;5(8):1232–1239. doi: 10.1200/JCO.1987.5.8.1232. [DOI] [PubMed] [Google Scholar]
  33. Wiernik P. H., Schwartz E. L., Strauman J. J., Dutcher J. P., Lipton R. B., Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 1987 May 1;47(9):2486–2493. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES